Matthew Gall

Insider Reports History

Entity
Individual
Location
C/O Iteos Therapeutics, Inc., 139 Main Street, Cambridge, MA
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew Gall:

Stock Role Class Num Shares Value Price $ Report Date Ownership
iTeos Therapeutics, Inc. Chief Financial Officer Common Stock 65.4K $506K $7.73 Nov 19, 2024 Direct
iTeos Therapeutics, Inc. Chief Financial Officer Stock Option (Right to Buy) 163K Mar 7, 2024 Direct

Insider Reports Filed by Matthew Gall

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ITOS iTeos Therapeutics, Inc. Nov 19, 2024 1 $38.6K 4 Nov 19, 2024 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Mar 7, 2024 1 $0 4 Mar 8, 2024 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Dec 5, 2023 1 $0 4 Dec 7, 2023 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Oct 12, 2023 1 $41.9K 4 Oct 12, 2023 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Mar 9, 2023 1 $0 4 Mar 10, 2023 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Mar 11, 2022 1 $0 4 Mar 14, 2022 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Dec 27, 2021 1 -$232K 4 Dec 28, 2021 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Oct 11, 2021 2 $88.9K 4 Oct 12, 2021 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Jun 24, 2021 1 $0 4 Jun 25, 2021 Chief Financial Officer
ITOS iTeos Therapeutics, Inc. Jun 16, 2021 1 $130K 4 Jun 16, 2021 Chief Financial Officer